Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brett Sperry

Advanced Heart Failure and Transplant Cardiology Kansas City, MO Medical Doctor

NPI 1982920534 CMS profile 362576

4330 Wornall Rd Ste 2000, Kansas City, MO 64111

Open in the dashboard

General payments

$313,931

227 records reported · program years 2019–2025

Research payments

$1,560

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$347,532 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Brett Sperry of Kansas City, MO is reported in the CMS Open Payments database as having received $313,931 across 227 general payments and $1,560 in research payments paid to them. Separately, studies naming them as principal investigator received $347,532 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82,823 69
2024 General $47,454 30
2024 Research $780 1
2023 General $40,000 39
2023 Research $780 1
2022 General $37,057 26
2021 General $38,977 19
2020 General $36,845 19
2019 General $30,775 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brett Sperry
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Brett Sperry were reported at $82,823. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Brett Sperry Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $30,775 $863 $224–$4,562 $163
2020 $36,845 $452 $122–$3,992 $114
2021 $38,977 $550 $159–$3,571 $132
2022 $37,057 $729 $221–$4,357 $149
2023 $40,000 $1,002 $309–$5,827 $160
2024 $47,454 $931 $273–$5,204 $164
2025 $82,823 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $177,892 94 payments
  2. Alnylam Pharmaceuticals Inc. $85,220 69 payments
  3. AstraZeneca Pharmaceuticals LP $34,527 22 payments
  4. Novartis Pharmaceuticals Corporation $9,587 7 payments
  5. AstraZeneca UK Limited $4,296 5 payments
  6. Abbott Laboratories $1,280 21 payments
  7. Alexion Pharmaceuticals, Inc. $479 3 payments
  8. Abiomed $196 2 payments
  9. Impulse Dynamics (USA) Inc. $188 1 payment
  10. Boston Scientific Corporation $137 1 payment
  11. Other $130 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $186,788 73 payments
  2. Consulting Fee $91,318 28 payments
  3. Travel and Lodging $20,029 46 payments
  4. Honoraria $10,800 1 payment
  5. Food and Beverage $4,920 77 payments
  6. Education $75 2 payments
Products named General payments · program years 2019–2025
  1. VYNDAQEL $175,174 88 payments
  2. AMVUTTRA $40,075 35 payments
  3. ONPATTRO $32,950 22 payments
  4. WAINUA $26,369 17 payments
  5. ENTRESTO $9,493 6 payments
  6. VYNDAMAX $2,717 6 payments
  7. CardioMEMS HF System $338 3 payments
  8. CARDIOMEMS Structural Heart $247 6 payments
  9. Optimizer Smart System $188 1 payment
  10. CARDIOMEMS Heart failure $161 3 payments
  11. Other $994 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $1,560 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

4,504

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$14,945,271

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

34.7%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 611 $14,123,619
Eliquis Apixaban Brand 238 $228,395
Jardiance Empagliflozin Brand 150 $160,089
Entresto Sacubitril/Valsartan Brand 143 $144,704
Farxiga Dapagliflozin Propanediol Brand 99 $96,506
Xarelto Rivaroxaban Brand 46 $52,019
Repatha Sureclick Evolocumab Brand 25 $27,807
Ozempic Semaglutide Brand 20 $25,732
Mounjaro Tirzepatide Brand 13 $16,086
Eplerenone Generic 98 $7,602

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$93,050

Medicare's payments for the services billed

Medicare patients

919

Average age 75

Services billed

2,154

391 women, 528 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Heart failure 58%
Atrial fibrillation 51%
Arthritis 50%
Chronic kidney disease 49%
Diabetes 41%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $21,474
$21,474 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $7,407
$7,407 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $94
$94 — —
VYNDAMAX
  • PFIZER INC. $78
$78 611 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record